{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-059127","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2026-05-19T21:17:03+00:00","discovered_at":"2026-05-19T21:18:00.293563+00:00","generated_at":"2026-05-19T21:19:58.017206+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaxart files preliminary proxy; urges support for board nominees amid dissident challenge","bullets":["Annual meeting set for July 16, 2026; preliminary proxy filed with SEC.","Dissident shareholder group nominated three candidates; company says they lack relevant biotech experience.","Cash resources ~$61M as of Q1 2026; funded runway into Q2 2027.","BARDA COVID-19 Phase 2b trial restored after stop-work order; main cohort primary readout expected early 2027.","CEO holds over 2.5M shares and has never sold a share; board added Dr. James Breitmeyer in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-059127","json":"https://secwatch.observer/filing/0001213900-26-059127.json","markdown":"https://secwatch.observer/filing/0001213900-26-059127.md","text":"https://secwatch.observer/filing/0001213900-26-059127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000121390026059127/0001213900-26-059127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000121390026059127/ea0291449-8k_vaxart.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T21:19:58.017206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}